Drugs, Poisons and Controlled Substances Act 1981 No

Total Page:16

File Type:pdf, Size:1020Kb

Drugs, Poisons and Controlled Substances Act 1981 No Authorised Version No. 120 Drugs, Poisons and Controlled Substances Act 1981 No. 9719 of 1981 Authorised Version incorporating amendments as at 1 July 2018 TABLE OF PROVISIONS Section Page 1 Short title and commencement 1 Part I—Introductory and transitional 2 2 Repeals and revocations 2 3 Savings 3 4 Definitions 5 4A Act does not apply to certain processed products 35 5 Meaning of possession 35 6 Meaning of corresponding law 36 7 Act not to derogate from provisions of certain other Acts 37 8 References in other Acts 37 9 Revocation of proclamation etc. 38 11 Act to bind the Crown 38 Part II—Poisons and controlled substances 40 Division 1—Classification 40 12 Poisons Code 40 12A The Poisons List 40 12B Requirements for labelling and other matters 42 12C What if the Poisons Code conflicts with the Act or regulations? 42 12D Incorporation of the Poisons Standard 43 12E Amendment of Code 43 12F Status of the Poisons Code 45 12G Procedure for preparation of the Poisons Code 46 12H Tabling before Parliament 46 12I Availability of Code 47 12J What if documents are not notified or made available? 48 12K Commencement of Poisons Code and incorporated materials 48 12L Evidence 49 Authorised by the Chief Parliamentary Counsel i Section Page Division 2—Authorized persons 50 13 Persons authorized to have possession etc. of poisons or controlled substances 50 13A Chinese medicine practitioners and herbal dispensers must establish therapeutic need 56 14 Restrictions on authorisations for certain health practitioners 57 14A Minister to approve scope of prescribing rights or supply of poisons 59 Division 3—Poisons Advisory Committee 61 15 Establishment and membership of Poisons Advisory Committee 61 15A Terms and conditions of appointment 62 15B Resignation and removal 63 15C Vacancies 63 15D Quorum and proceedings 64 15E Co-opted members 64 16 Sub-committees 65 17 Functions of the Committee 65 18 Officers of committee 66 Division 4—Licences, permits and warrants 66 18A Definitions 66 19 Issue of licences, permits and warrants 67 20 What a licence, permit or warrant can authorise 69 21 Duration of a licence, permit or warrant 71 22 Renewal of licences and permits 71 22A Amendment 72 22B Inspection 72 22C Suspension or cancellation 72 Division 5—Public health emergencies 73 22D When a public health emergency order may be made 73 22E Matters to be specified in a public health emergency order 74 22F What a public health emergency order authorises 74 22G Extending, amending and revoking orders 75 22H Orders under this Division to be published in Government Gazette 75 Division 8—Manufacture and sale of poisons or controlled substances 76 23 Manufacture, sale and supply of poisons or controlled substances by wholesale 76 24 Wholesaling of certain poisons 76 26 Retailing of poisons or controlled substances 77 Authorised by the Chief Parliamentary Counsel ii Section Page 27 Sale of poisons or controlled substances by persons other than manufacturers etc. 77 27A Offences concerning labelling and other matters 78 28 House to house sale of poisons or controlled substances prohibited 80 29 Sale of substances in unauthorised containers 80 30 Vending machines for poisons or controlled substances 81 Division 9—Monitored poisons database 82 30A Secretary may establish monitored poisons database 82 30B Powers of Secretary in relation to monitored poisons database 83 30C Access, use and disclosure of information on monitored poisons database 85 30D Data source entity to provide records and information to monitored poisons database 87 30E Pharmacist to check monitored poisons database before supply of monitored supply poison 87 30F Registered medical practitioner to check monitored poisons database before prescription or supply of monitored supply poison 88 30G Nurse practitioner to check monitored poisons database before prescription or supply of monitored supply poison 88 30H Authorised supplier to check monitored poisons database before prescription or supply of monitored supply poison 88 30I Offences relating to access or use of monitored poisons database unless authorised 89 30J Protection from liability for duties and functions in relation to monitored poisons database 89 Division 10—Drugs of dependence, Schedule 8 poisons, Schedule 9 poisons and Schedule 4 poisons 90 Subdivision 1—Introductory matters and records 90 31 Definitions 90 31A Division does not apply to medicinal cannabis 92 32 Record keeping in relation to sale or supply of drugs of addiction 92 32A Required notification to Secretary—drugs of dependence and Schedule 4, Schedule 8 and Schedule 9 poisons 93 Subdivision 3—Schedule 9 poisons 94 33A Application for permit to administer, supply or prescribe Schedule 9 poisons 94 33B Schedule 9 permit 95 33C Offence not to comply with Schedule 9 permit 95 33D Offence to administer Schedule 9 poisons without permit 96 Authorised by the Chief Parliamentary Counsel iii Section Page Subdivision 4—Schedule 8 poisons 96 34 Requirement to apply for Schedule 8 permit 96 34A Schedule 8 permit 97 34B Offence to administer etc. Schedule 8 poisons to drug- dependent person 98 34C Offence to administer etc. Schedule 8 poisons to person who is not a drug-dependent person 98 34D Exception to Schedule 8 permit requirement—specified circumstances 100 34E Exceptions to Schedule 8 permit requirement—multiple practitioners at medical clinic 100 34F Exception to Schedule 8 permit requirement—patients in prisons, police gaols, aged care services and hospitals 102 35 Offence not to comply with Schedule 8 permit 103 Subdivision 5—General 103 35A Secretary may specify circumstances for purposes of section 34D 103 35B Composite forms 104 36A Forgery 104 36B Unauthorized possession etc. of poison or controlled substance etc. 104 Division 10A—Administration of medication in aged care services 106 36C Effect of this Division 106 36D Definitions 106 36E Administration of drugs of dependence, Schedule 9 poisons, Schedule 8 poisons and Schedule 4 poisons in aged care services 107 36F Registered nurse to have regard to code or guideline 107 Division 11—Appeals 108 37 Appeals 108 Division 12—Sale of poisons book 108 38 Record of sale of poisons 108 38A Authorised possession of certain poisons 108 40 Sale or supply of poisons or controlled substances to persons under age 109 Division 13—Authorized officers 109 41 Secretary may authorize person to carry out functions of authorized officer 109 42 Inspections 110 42A Powers of authorized officers to access, use and disclose information on monitored poisons database 112 Authorised by the Chief Parliamentary Counsel iv Section Page 43 Duties of officers in relation to seized substances 112 44 Persons who are liable for contravention of Act 114 Division 13A—Authorised police employees and other authorised persons 116 44A Chief Commissioner may authorise person to carry out functions of authorised police employee 116 44B Powers, duties and functions of authorised police employee 117 44C Other authorised persons 117 Division 14—Offences 118 45 Time within which charge-sheet to be filed 118 46 Offences 119 47 Maximum sentence etc. 119 48 Offence to receive certain moneys etc. 120 49 Obtaining licence by fraud 120 50 Immunity of authorized officers and authorised police employees 120 Division 15—Poison baits 121 52 Setting of poison baits 121 53 Regulations 124 Division 16—Poisons in roads and waterways 124 54 Special regulations 124 Division 17—Prohibition of poisons or controlled substances 125 55 Prohibiting sale or supply of poisons or controlled substances 125 Part IIA—Trial of medically supervised injecting centre 127 Division 1—Preliminary 127 55A Object 127 55B Meaning of director and supervisor of licensed medically supervised injecting centre 128 Division 2—Medically supervised injecting centre licence 129 55C Medically supervised injecting centre may be licensed for trial period 129 55D Only one licence may be issued 130 55E Internal management protocols 130 55F Trial period for licensed medically supervised injecting centre 132 55G Notices regarding licence 132 55H Conditions of medically supervised injecting centre licence 134 Authorised by the Chief Parliamentary Counsel v Section Page 55I Disciplinary action for contravening licence condition or internal management protocols 134 55J Secretary's power to revoke licence 135 Division 3—Miscellaneous 136 55K Exemptions from criminal liability and authorizations for clients of centre 136 55L Exemptions from criminal liability and authorizations for licensee and staff 137 55M Police discretions not affected 138 55N Exemption from civil liability 138 55O Planning permit not required 140 55P Review of this Part and licensing of medically supervised injecting centre for trial period 140 55Q Regulations for this Part 141 55R Repeal of this Part and related amendments 143 Part III—Manufacture of heroin 144 56 Manufacture of heroin etc. 144 Part IIIA—Psychoactive substances 148 56A Definitions 148 56B Burden of proof 148 56C Representation that not for human consumption not a defence 148 56D Offence to produce psychoactive substance 149 56E Offence to sell or supply psychoactive substance 149 56F Offence to advertise psychoactive substance 150 Part IV—Deleterious substances and search, seizure and detention powers relating to volatile substances 151 Division 1—Deleterious substances 151 57 Definitions 151 58 Sale of deleterious substances 152 59 Matters to which this Part does not apply 153 60 Evidence 153 Division 2—Volatile substances 154 60A Purpose of Division 154 60B Police or
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Medicines Regulations 1984 (SR 1984/143)
    Reprint as at 1 July 2014 Medicines Regulations 1984 (SR 1984/143) David Beattie, Governor-General Order in Council At the Government House at Wellington this 5th day of June 1984 Present: His Excellency the Governor-General in Council Pursuant to section 105 of the Medicines Act 1981, and, in the case of Part 3 of the regulations, to section 62 of that Act, His Excellency the Governor-General, acting on the advice of the Minister of Health tendered after consultation with the organisations and bodies that ap- peared to the Minister to be representatives of persons likely to be substantially affected, and by and with the advice and consent of the Executive Council, hereby makes the following regulations. Contents Page 1 Title and commencement 5 Note Changes authorised by subpart 2 of Part 2 of the Legislation Act 2012 have been made in this official reprint. Note 4 at the end of this reprint provides a list of the amendments incorporated. These regulations are administered by the Ministry of Health. 1 Reprinted as at Medicines Regulations 1984 1 July 2014 2 Interpretation 5 Part 1 Classification of medicines 3 Classification of medicines 11 Part 2 Standards 4 Standards for medicines, related products, medical 11 devices, cosmetics, and surgical dressings 5 Pharmacist may dilute medicine in particular case 12 6 Colouring substances [Revoked] 12 Part 3 Advertisements 7 Advertisements not to claim official approval 13 8 Advertisements for medicines 13 9 Advertisements for related products 15 10 Advertisements for medical devices 15 11 Advertisements
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • A10 Anabolic Steroids Hardcore Info
    CONTENTS GENERAL INFORMATION 3 Anabolic steroids – What are they? 4 How do they Work? – Aromatisation 5 More molecules – More problems 6 The side effects of anabolic steroids 7 Women and anabolic steroids 8 Injecting steroids 9 Abscesses – Needle Exchanges 10 Intramuscular injection 11 Injection sites 12 Oral steroids – Cycles – Stacking 13 Diet 14 Where do steroids come from? Spotting a counterfeit 15 Drug Information – Drug dosage STEROIDS 16 Anadrol – Andriol 17 Anavar – Deca-Durabolin 18 Dynabolon – Durabolin – Dianabol 19 Esiclene – Equipoise 20 Primobolan Depot – Proviron – Primobolan orals – Pronobol 21 Sustanon – Stromba, Strombaject – Testosterone Cypionate Testosterone Enanthate 22 Testosterone Propionate – Testosterone Suspension 23 Trenbolone Acetate – Winstrol OTHER DRUGS 24 Aldactone – Arimidex 25 Clenbuterol – Cytomel 26 Ephedrine Hydrochloride – GHB 27 Growth Hormone 28 Insulin 30 Insulin-Like Growth Factor-1 – Human Chorionic Gonadotrophin 31 Tamoxifen – Nubain – Recreational Drugs 32 Steroids and the Law 34 Glossary ANABOLIC STEROIDS People use anabolic steroids for various reasons, some use them to build muscle for their job, others just want to look good and some use them to help them in sport or body building. Whatever the reason, care needs to be taken so that as little harm is done to the body as possible because despite having muscle building effects they also have serious side effects especially when used incorrectly. WHAT ARE THEY? Anabolic steroids are man made versions of the hormone testosterone. Testosterone is the chemical in men responsible for facial hair, deepening of the voice and sex organ development, basically the masculine things Steroids are in a man. used in medicine to treat anaemia, muscle weakness after These masculine effects surgery etc, vascular are called the androgenic disorders and effects of testosterone.
    [Show full text]
  • Texas Controlled Substances Act
    HEALTH AND SAFETY CODE TITLE 6. FOOD, DRUGS, ALCOHOL, AND HAZARDOUS SUBSTANCES SUBTITLE C. SUBSTANCE ABUSE REGULATION AND CRIMES CHAPTER 481. TEXAS CONTROLLED SUBSTANCES ACT SUBCHAPTER A. GENERAL PROVISIONS Sec.A481.001.AASHORT TITLE. This chapter may be cited as the Texas Controlled Substances Act. Acts 1989, 71st Leg., ch. 678, Sec. 1, eff. Sept. 1, 1989. Sec.A481.002.AADEFINITIONS. In this chapter: (1)AA"Administer" means to directly apply a controlled substance by injection, inhalation, ingestion, or other means to the body of a patient or research subject by: (A)AAa practitioner or an agent of the practitioner in the presence of the practitioner; or (B)AAthe patient or research subject at the direction and in the presence of a practitioner. (2)AA"Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser. The term does not include a common or contract carrier, public warehouseman, or employee of a carrier or warehouseman acting in the usual and lawful course of employment. (3)AA"Commissioner" means the commissioner of state health services or the commissioner 's designee. (4)AA"Controlled premises" means: (A)AAa place where original or other records or documents required under this chapter are kept or are required to be kept; or (B)AAa place, including a factory, warehouse, other establishment, or conveyance, where a person registered under this chapter may lawfully hold, manufacture, distribute, dispense, administer, possess, or otherwise dispose of a controlled substance or other item governed by the federal Controlled Substances Act (21 U.S.C.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • List of Narcotic Substances Circulation of Which Is Restricted in Uzbekistan
    List of narcotic substances circulation of which is restricted in Uzbekistan 1. 2C-B(4-bromo-2,5-dimethoxyphenethylamine) 2. 3-methylfentanyl 3. 3-methylthiofentanyl 4. 3-Monoacetylmorphine 5. 4-methylaminorex 6. 6- Monoacetylmorphine 7. Acetorphine 8. Acetyl Dihydrocodeine 9. Acetyl-alfametilfentanil 10. Acetylated opium 11. Acetylcodeine 12. Acetylmethadol 13. Alfametadol 14. Alfatsetilmetadol 15. all fungi that contain Psilocine and Psilocybine 16. Allylprodine 17. Alpha Methylfentanyl 18. Alpha Metiltiofentanil 19. Alphaprodine 20. Anileridin 21. Benzethidine 22. Benzylmorphine 23. Betacetylmethadol 24. Betahydroxyfentanyl 25. Betameprodine 26. Betamethadol 27. Betaprodine 28. Bezitramide 29. Cannabis oil (hashish oil) 30. Cannabis, marihuana 31. Cathine ((+)-norpseudoephedrine) 32. Cathinone (l-alpha-aminopropiofenon) 33. Clonitazene 34. Cocaine 35. Codoxime 36. d- Methadone 37. DB [L-(3,4 - methylenedioxyphenyl) -2 butanamine] 38. Desmethylprodine; MPPP (1-methyl-4-phenyl-4-propionoxypiperidine) 39. Desomorphine 40. DET (N,N-diethyltryptamine) 41. Dexamphetamine 42. Diampromide 43. Diethyl phosphate 44. Diethylthiambutene 45. Dihydromorphine 46. Dimenoxadol 47. Dimepheptanol 48. Dimethylthiambutene 49. Dioxaphetyl butyrate 50. Diphenoxine 51. Dipipanone 52. DMA (2,5-dimethoxyamphetamine) 53. DMGP (dimetilgeptilpiran) 54. DMT (dimethyltryptamine) 55. DOB (d, L-2,5-dimethoxy-4-bromo-amphetamine) 56. DOC (d, L-2,5-dimethoxy-4-chloro-amphetamine) 57. DOET (2,5-dimethoxy-4-ethylamphetamine) 58. Drotebanol 59. Ecgonine 60. Ephedrone 61. Ethylmethylthiambutene 62. Eticyclidine 63. Etonitazene 64. Etorphine 65. Etoxeridine 66. Etryptamine 67. Furethidine 68. Hashish (Anasha, cannabis resin) 69. Heroin (Diacetylmorphine) 70. Hydrocodone 71. Hydrocodone phosphate 72. Hydromorphinol 73. Hydromorphone 74. Isomethadone 75. Ketobemidone 76. Khat 77. L- Methadone 78. Levomethorphan 79. Levomoramide 80. Levophenacylmorphan 81. Levorphanol 82. Lysergic acid and its preparations, that include d-Lysergide (LSD, LSD-25) 83.
    [Show full text]
  • Schedules of Controlled Substances (.Pdf)
    PURSUANT TO THE TEXAS CONTROLLED SUBSTANCES ACT, HEALTH AND SAFETY CODE, CHAPTER 481, THESE SCHEDULES SUPERCEDE PREVIOUS SCHEDULES AND CONTAIN THE MOST CURRENT VERSION OF THE SCHEDULES OF ALL CONTROLLED SUBSTANCES FROM THE PREVIOUS SCHEDULES AND MODIFICATIONS. This annual publication of the Texas Schedules of Controlled Substances was signed by John Hellerstedt, M.D., Commissioner of Health, and will take effect 21 days following publication of this notice in the Texas Register. Changes to the schedules are designated by an asterisk (*). Additional information can be obtained by contacting the Department of State Health Services, Drugs and Medical Devices Unit, P.O. Box 149347, Austin, Texas 78714-9347. The telephone number is (512) 834-6755 and the website address is http://www.dshs.texas.gov/dmd. SCHEDULES Nomenclature: Controlled substances listed in these schedules are included by whatever official, common, usual, chemical, or trade name they may be designated. SCHEDULE I Schedule I consists of: -Schedule I opiates The following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, if the existence of these isomers, esters, ethers, and salts are possible within the specific chemical designation: (1) Acetyl-α-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide); (2) Acetylmethadol; (3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide); (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide) (Other name:
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 De Juan Et Al
    US 20110159073A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 de Juan et al. (43) Pub. Date: Jun. 30, 2011 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA A6F 2/00 (2006.01) (US); Signe E. Varner, Los (52) U.S. Cl. ........................................................ 424/427 Angeles, CA (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Featured is a method for instilling one or more bioactive (21) Appl. No.: 12/981,038 agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising con (22) Filed: Dec. 29, 2010 currently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a Sustained release Related U.S. Application Data delivery device comprising one or more bioactive agents in a (63) Continuation of application No. 1 1/175,850, filed on posterior region of the eye so that it delivers the one or more Jul. 5, 2005, now abandoned. bioactive agents into the vitreous humor of the eye; (B) instill ing (e.g., injecting or implanting) one or more bioactive (60) Provisional application No. 60/585,236, filed on Jul. 2, agents Subretinally; and (C) instilling (e.g., injecting or deliv 2004, provisional application No. 60/669,701, filed on ering by ocular iontophoresis) one or more bioactive agents Apr. 8, 2005. into the vitreous humor of the eye. Patent Application Publication Jun. 30, 2011 Sheet 1 of 22 US 2011/O159073 A1 Patent Application Publication Jun.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
    [Show full text]
  • Medicines, Poisons and Therapeutic Goods Regulation 2008
    Australian Capital Territory Medicines, Poisons and Therapeutic Goods Amendment Regulation 2009 (No 1) Subordinate Law SL2009-27 The Australian Capital Territory Executive makes the following regulation under the Medicines, Poisons and Therapeutic Goods Act 2008. Dated 1 June 2009. KATY GALLAGHER Minister SIMON CORBELL Minister J2009-295 Authorised by the ACT Parliamentary Counsel—also accessible at www.legislation.act.gov.au Australian Capital Territory Medicines, Poisons and Therapeutic Goods Amendment Regulation 2009 (No 1) Subordinate Law SL2009-27 made under the Medicines, Poisons and Therapeutic Goods Act 2008 1 Name of regulation This regulation is the Medicines, Poisons and Therapeutic Goods Amendment Regulation 2009 (No 1). 2 Commencement This regulation commences on the day after its notification day. Note The naming and commencement provisions automatically commence on the notification day (see Legislation Act, s 75 (1)). 3 Legislation amended This regulation amends the Medicines, Poisons and Therapeutic Goods Regulation 2008. J2009-295 Authorised by the ACT Parliamentary Counsel—also accessible at www.legislation.act.gov.au Section 4 4 Table 850, note omit AAT substitute ACAT 5 Sections 851 and 852 substitute 851 Reviewable decision notices If a person makes a reviewable decision, the person must give a reviewable decision notice to each entity mentioned in table 850, column 4 in relation to the decision. Note 1 The person must also take reasonable steps to give a reviewable decision notice to any other person whose interests are affected by the decision (see ACT Civil and Administrative Tribunal Act 2008, s 67A). Note 2 The requirements for reviewable decision notices are prescribed under the ACT Civil and Administrative Tribunal Act 2008.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]